Shares of Cipla Ltd. sank 1.51% on a routine current Good Manufacturing Practices (cGMP) inspection conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of the Company located in Patalganga, Maharashtra, India from March 28 2024 to April 4 2024.

On conclusion of the inspection, the company has received 6 inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to addressing these comprehensively within the stipulated time.

Earlier on March 26, 2024Sanofi India Limited (SIL), Sanofi Healthcare India Private Limited (together referred to as Sanofi India) and Cipla Limited (Cipla) today announced an exclusive partnership for the distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India.

As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands, including Frisium, a leading brand in the anti-epileptic medication category.

While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally,

Before that, on February 26, 2024, Cipla Limited, hereafter referred to as Cipla, received approval from the Central Drugs Standard Control Organization (CDSCO) to market the novel antibiotic plazomicin in India.

Plazomicin is a new intravenous (IV) aminoglycoside indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis.

However, at 3:24 pm, the shares of Cipla Ltd. were trading flat at Rs 1,449.85 on NSE.